Open Access

Emergence of blaTEM, blaCTX‑M, blaSHV and blaOXA genes in multidrug‑resistant Enterobacteriaceae and Acinetobacter baumannii in Saudi Arabia

  • Authors:
    • Mutasim E. Ibrahim
    • Tarig B. Algak
    • Mohammed Abbas
    • Bahaeldin K. Elamin
  • View Affiliations

  • Published online on: October 14, 2021     https://doi.org/10.3892/etm.2021.10885
  • Article Number: 1450
  • Copyright: © Ibrahim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Multidrug‑resistant (MDR) patterns due to extended‑spectrum β‑lactamase (ESBL) production in pathogenic bacteria are now becoming prevalent in hospitals worldwide, posing a public health challenge. The aim of the present study was to determine the antibiotic susceptibility patterns and distribution of the blaTEM, blaCTX‑M, blaSHV and blaOXA ESBL resistance genes in MDREnterobacteriaceae and Acinetobacter baumannii (A. baumannii). A cross‑sectional study was conducted between September 2017 and August 2018 in the King Abdullah Hospital (Bisha, Saudi Arabia). Bacterial isolates were collected from the clinical samples of patients; these were identified and screened for ESBL production and their antibiotic susceptibility was examined using standard microbiology methods. Multiplex‑PCR runs were performed to identify genes encoding ESBL producers. DNA sequencing analysis was used to identify the specific gene variants. Of the 274 isolates, 173 (63.1%) exhibited MDR patterns to different antibiotics. A. baumannii revealed the highest resistance rates for cefuroxime (100%), gentamicin (88%) and amikacin (86%). Klebsiella pneumoniae (K. pneumoniae) isolates had the highest resistance rates for cefuroxime (98%), aztreonam and trimethoprim/sulfamethoxazole (87% for each). Escherichia coli (E. coli) exhibited high resistance rates for trimethoprim/sulfamethoxazole (92%) and cefuroxime (87%). Of the 173 MDR isolates, 78 (45.1%) exhibited ESBL production. Of these, 88.9% (72/78) carried ESBL genes. The most prevalent gene‑encoding isolates were blaTEM (84.7%), followed by blaCTX‑M (33.3%), blaSHV (2.7%) and blaOXA‑1 (1.4%). A single blaTEM gene was predominantly produced by K. pneumoniae (60.7%), A. baumannii (78.9%) and Proteus mirabilis (80%), whereas blaCTX‑M was harbored by E. coli (33.3%). The co‑existence of two different genes in a single bacterium was revealed in 22.2% of isolates, commonly between blaTEM and blaCTX‑M (19.4%). Sequencing analysis revealed that blaCTX‑M‑15 and blaTEM‑1 were predominant variants of the blaCTX‑M and blaTEM genes, respectively. The present study revealed a diversity of ESBL genes in Gram‑negative bacterial isolates, with blaTEM being the most prevalent type. The emergence of various ESBL genes with several co‑existing genotypes is alarming, rendering extensive surveillance studies necessary to understand the transmission and epidemiology of such resistant gene‑carrying isolates.

Introduction

In recent years, the production of extended-spectrum β-lactamases (ESBL) has become the main mechanism of resistance to β-lactam and other antibiotics in Enterobacteriaceae and Acinetobacter baumannii (A. baumannii) (1). ESBL enzymes confer resistance to penicillins, cephalosporins, monobactams and other antibiotic classes (2). Multidrug-resistant (MDR) patterns due to ESBL production in pathogenic bacteria are now becoming prevalent in hospitals worldwide, posing a public health challenge, including treatment failure, prolonged hospital stay and increased mortality rates (3-5).

Recently, >300 different ESBL types have been described in Gram-negative bacteria (6,7). The blaTEM and blaSHV types have been recognized as the most prevalent ESBL genes conferring antibiotic resistance in pathogenic bacteria worldwide (8-10). Previous studies have revealed that the number of clinical isolates harboring the blaCTX-M gene type has also increased in the last few years (2,11). The blaCTX-M family includes >130 β-lactamase variants classified into five distinct groups: blaCTX-M-1, blaCTX-M-2, blaCTX-M-8, blaCTX-M-9 and blaCTX-M-25 (12).

The genetic diversity of ESBL-producing Enterobacteriaceae and A. baumannii has progressively increased, posing challenges to hospital authorities due to their ability to confer antibiotic susceptibility and limit therapeutic options (13,14). The characterization of resistance genes encoding ESBL-producing microorganisms is a powerful tool for developing evidence-based guidelines for combating antibiotic resistance in the clinical setting (11).

In Saudi Arabia, Gram-negative bacteria-harboring ESBL resistance genes have been studied, with most studies emerging from the central and eastern regions (5,15-19). Despite the spread of antibiotic resistance among bacterial pathogens in the southern region, data on the distribution of ESBL resistance genes and their resistance profile among Enterobacteriaceae and A. baumannii remain limited (20,21). A previous study performed at the Aseer Central Hospital, a regional hospital in the southern region, identified MDR patterns among 98.1% of Acinetobacter species recovered from patients at intensive care units (22). In addition, another study conducted in the same hospital identified a high distribution of class D carbapenemase-encoding genes in A. baumannii, mainly ISAba1/OXA-23 and ISAba1/OXA-24 carbapenemases, which is alarming and presents an emerging public health threat (23). The emergence of MDR A. baumannii bacteremia in the southern region of Saudi Arabia has been well documented as an important health problem (22,24,25). A recent study reported the high frequency of MDR Gram-negative bacteria and a rate of ESBL production of 27% in patients at the King Abdullah Hospital, a referral hospital in Bisha, in the southern region of the country (20).

Due to the lack of information on the genotyping of ESBL producers and their MDR patterns in southern Saudi Arabia, the present study aimed to determine the antibiotic susceptibility patterns and distribution of ESBL genes in Enterobacteriaceae and A. baumannii isolates collected from clinical specimens of patients. The findings of the present study facilitated the implementation of infection control measures and provided epidemiological data to prevent spreading of MDR bacteria. The data also provided guidelines for the use of antibiotics in the clinical settings and improved the management of patients suffering from infections caused by Enterobacteriaceae and A. baumannii.

Materials and methods

Study design and setting

A cross-sectional study was conducted between September 2017 and August 2018 at the King Abdullah Hospital (Bisha, Saudi Arabia). A total of 274 Enterobacteriaceae and A. baumannii were recovered from patients as a part of the treatment and diagnosis procedure for infections. The clinical samples were collected from the patients as a part of routine investigations of infectious agents in the hospital microbiology laboratory. Therefore, consent letters were not obtained from the patients as per the study nature. Various clinical samples of urine (n=96), sputum (n=84), wound swab (n=51), blood (n=27), high vaginal swab (n=5), tracheal aspirate (n=5), umbilical discharge (n=3), cerebrospinal fluid (n=2) and eye swab (n=1) collected from 274 patients suffering from different bacterial infections were included in the study. Discharge from umbilical stump was collected from neonatal and/or infant patients in the wards using sterile swab soaked with normal saline and submitted to the laboratory. High vaginal swab was taken from female patients by clinicians and sent for microbiological examinations. Clinical specimens with incomplete personal information of the patients were excluded from the study. The average age of the patients was 46.0±25.5 years, including 158 females and 116 males. In total, 32 patients were aged 2-17 years, 97 were aged 18-40 years, 57 were aged 41-65 years and 88 were aged >65years. Patients of <2 years old were excluded from the study. The hospital is a referral hospital in the southern region (365 beds) with different specialties serving the Bisha province and the surrounding areas. The Research and Ethics committee at the College of Medicine, University of Bisha (Bisha, Saudi Arabia) reviewed and approved the present study protocol (approval no. UBCOM/1438-05/04).

Isolation and identification of bacteria

Enterobacteriaceae and A. baumannii were collected from the microbiology laboratory of King Abdullah Hospital during the routine processing of the clinical specimens of patients. Preliminary isolation and identification of bacteria were based on conventional microbiological methods. Briefly, Isolation of bacterial pathogens from specimens of urine, stool, sputum and other body fluids were performed by inoculating one loopful of each sample onto MacConkey agar plates (Oxoid, Ltd.) using a sterile disposable plastic loop (10-µl loop). Specimens of wounds, eye, umbilical and vaginal swabs were inoculated directly onto MacConkey agar plates by streaking them onto a small area of the plate. A disposable sterile plastic loop (1-µl loop) was used for cross-streaking to spread the inoculum over the surface of each plate to obtain single colonies of the suspected bacterial pathogen. Specimen of blood (5 ml) were extracted under aseptic conditions, transferred immediately into sterile bottles containing brain heart infusion broth (Oxoid, Ltd.), incubated at 37˚C with 5% CO2 and examine daily for turbidity for ≤7 days. If turbidity was observed, a 10-µl loopful of the blood sample was subcultured onto MacConkey agar plates for isolation of the suspected Gram-negative pathogen after aerobic incubation at 37˚C for 24 h. The isolate was tentatively identified based on the colony morphology, gram staining and oxidase test and the API 20 E Gram-Negative Microbial Identification Kit (cat. no. 20160; bioMerieux SA). Then, full identification of bacterial isolates was confirmed using the Phoenix system identification assay (Becton, Dickinson and Company). One single bacterial isolate from the clinical sample of each patient was included in the present study.

Screening of ESBL production

Phenotypic ESBL production among isolates was examined using a double-disc synergy test (DDST) as previously described (26) and the decreased susceptibility to cefuroxime, ceftazidime and cefotaxime was examined according to the Clinical and Laboratory Standard Institute (CLSI) recommendations (27). Bacterial isolates yielded positive results with DDST, when subjected to a multiplex-PCR amplification assay to detect blaTEM, blaSHV, blaCTX-M and blaOXA-1 resistance genes.

Antibiotic susceptibility testing of ESBL-producing bacteria

Antibiotic susceptibility testing of the Enterobacteriaceae and A. baumannii was performed using the Kirby-Bauer disk diffusion method on Mueller-Hinton agar medium (Oxoid) as per the CLSI guidelines (27). The following antibiotics with known concentrations recommended by the CLSI were examined: Amikacin (30 µg), amoxicillin/clavulanate (20/10 µg), aztreonam (30 µg), cefepime (30 µg), cefotaxime (30 µg), cefoxitin (30 µg), ceftazidime (30 µg), cefuroxime (30 µg), ciprofloxacin (5 µg), colistin (10 µg), gentamicin (10 µg), imipenem (10 µg), meropenem (10 µg), nitrofurantoin (50 µg), piperacillin (100 µg), piperacillin/tazobactam (100/10 µg), tobramycin (10 µg) and trimethoprim/sulfamethoxazole (23.75 µg/1.25 µg; Oxoid). E. coli American Type Culture Collection (ATCC) 25922 served as a control strain for antibiotic susceptibility examination. The final antibiotic susceptibility results of bacterial pathogens were interpreted using the 2017 CLSI breakpoints to categorize the isolates as susceptible or resistant. All intermediate results were considered resistant strains. ‘A susceptible category indicates that the isolates of the patient respond to the usually achievable concentrations of that antibiotic when the dosage is recommended to treat that type of infection and bacterial species. Conversely, the resistant category indicates that the isolates of the patient are not inhibited by the usually achievable concentrations of that antibiotic with the dosages usually used with that drug’ (27). Isolates were defined as MDR when they were resistant to at least three antibiotics from different classes.

Multiplex-PCR for the detection of ESBL genes

Multiplex-PCR runs were performed to identify the blaTEM, blaSHV, blaCTX-M and blaOXA-1 genes. A pair of six specific oligonucleotide primers (Eurofins Scientific) were used in the PCR reaction, as previously described (28). DNA was extracted from ESBL-producing isolates using the boiling method as previously described (29). The amplification of ESBL genes was then carried out in a total reaction volume of 50 µl. Each reaction mixture contained 25 µl HotStarTaq Plus Master Mix (cat. no. 203643; Qiagen GmbH), 4 µl DNA template, a variable volume of a specific primer group (Table I) and 9 µl nuclease-free water. The Eppendorf Master cycler Gradient instrument (Eppendorf) was used for the amplification of target genes with the following optimal cycling conditions: Initial heat activation at 95˚C for 5 min, 35 cycles of denaturation at 94˚C for 45 sec, annealing at 53˚C for 45 sec, extension at 72˚C for 1 min and a final extension at 72˚C for 10 min. The amplification products were visualized under ultraviolet illumination at a wavelength of 312 nm, after running at 85 volts for 60 min on 2% agarose containing ethidium bromide (1 µg/ml). A 100-bp DNA ladder (cat. no. 239045; Qiagen GmbH) was used as a standard molecular weight to determine the size of PCR products. DNA from reference blaCTX-M, blaTEM, blaSHV and blaOXA-like-positive strains was used as a positive control.

Table I

The frequency of extended-spectrum β-lactamase resistance genes among Gram-negative bacteria (n=72) as detected by multiplex PCR using different primers.

Table I

The frequency of extended-spectrum β-lactamase resistance genes among Gram-negative bacteria (n=72) as detected by multiplex PCR using different primers.

 Oligonucleotide primer (28)
Resistance geneN (%)SequenceLengthBand size (base pairs)
blaTEM61 (84.7)F: 5'-CATTTCCGTGTCGCCCTTATTC-3'22800
  R: 5'-CGTTCATCCATAGTTGCCTGAC-3'22 
blaCTX-M24 (33.3)   
     blaCTX-M20 (27.2)F: 5'-TTAGGAARTGTGCCGCTGYA-3'20688
     group 1 R: 5'-CGATATCGTTGGTGGTRCCAT-3'21 
     blaCTX-M3 (4.2)F: 5'-CGTTAACGGCACGATGAC-3'18404
     group 2 R: 5'-CGATATCGTTGGTGGTRCCAT-3'21 
     blaCTX-M3 (4.2)F: 5'-TCAAGCCTGCCGATCTGGT-3'19561
     group 9 R: 5'-TGATTCTCGCCGCTGAAG-3'18 
     blaCTX-M0.0F: 5'-AACRCRCAGACGCTCTAC-3'18326
     group 8/25 R: 5'-TCGAGCCGGAASGTGTYAT-3'19 
blaSHV2 (2.7)F: 5'-AGCCGCTTGAGCAAATTAAAC-3'21713
  R: 5'-ATCCCGCAGATAAATCACCAC-3'21 
blaOXA-11 (1.4)F: 5'-GGCACCAGATTCAACTTTCAAG-3'22564
  R: 5'-GACCCCAAGTTTCCTGTAAGTG-3'22 

[i] F, forward; R, reverse.

DNA sequencing

Random PCR products of blaTEM-, blaSHV-, blaCTX-M- and blaOXA-1-positive samples were selected for DNA sequencing to identify the specific gene subtypes. A total of ~30 µl PCR products were sealed in sterile Eppendorf tubes and sent to Macrogen, Inc. for sequencing. PCR products were sequenced on an ABI PRISM® 3730XL Analyzer (96 capillary types) using the same primer sets (Table I). The results were obtained from the website of the company. Similarities in the nucleotide sequences were compared on the GenBank database of the National Center for Biotechnology Information website using the Basic Local Alignment Search Tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The sequences obtained for blaTEM, blaCTX-M and blaSHV genes have been deposited in the GenBank database (http://getentry.ddbj.nig.ac.jp/) under accession numbers LC636038 to LC636063.

Statistical analysis

Statistical analysis was performed using SPSS 22.0 (IBM Corp.). Simple descriptive statistics were used to calculate antibiotic-resistant patterns, and the prevalence and distribution of ESBL resistance genes. Outcome data were stated as proportions in frequencies and means ± standard deviation.

Results

Bacterial isolates

A total of 274 Enterobacteriaceae and A. baumannii isolates obtained from the clinical samples of patients were used in the present study. The isolates were recovered from samples of urine, sputum, wound swab, blood, high vaginal swab, tracheal aspirate, umbilical discharge, eye swab and cerebral spinal fluid. This indicated that Enterobacteriaceae and A. baumannii could cause infections throughout body systems and sites, including genito-urinary, respiratory, bloodstream, central nervous and soft tissue infections, which was consistent with a recent study (30).

Resistance patterns of Enterobacteriaceae and A. baumannii

Out of the 274 isolates, 63.1% (n=173) exhibited MDR patterns to different classes of antibiotics. Fig. 1 illustrated the MDR patterns among different isolates. The MDR pattern was determined in 100% of A. baumannii, 63.5% of Klebsiella pneumoniae (K. pneumoniae), 54.8% of Proteus mirabilis (P. mirabilis) and 51.8% of E. coli isolates.

Table II summarized the antibiotic susceptibility of MDR isolates. A. baumannii exhibited the highest resistance rates to the tested antibiotics (86% for amikacin, 88% for gentamicin and 100% for cefuroxime). K. pneumoniae exhibited the highest resistance rates for cefuroxime (98%), aztreonam and trimethoprim/sulfamethoxazole (87% each), and cefotaxime (83%). E. coli exhibited high resistance rates for trimethoprim/sulfamethoxazole (92%), cefuroxime (87%) and ceftazidime (71%). P. mirabilis exhibited high resistance rates for trimethoprim/sulfamethoxazole (100%), amoxicillin/clavulanate, cefotaxime, cefuroxime (88% each), cefepime, ciprofloxacin (82% each) and ofloxacin (77%).

Table II

Percentage of antimicrobial resistance among multidrug-resistant Acinetobacter baumannii and Enterobacteriaceae family members.

Table II

Percentage of antimicrobial resistance among multidrug-resistant Acinetobacter baumannii and Enterobacteriaceae family members.

 A. baumanniiK. pneumoniaeE. coliProteus mirabilisEnterobacter cloacaeCitrobacter freundiiProvidencia rettgeriProteus vulgarisMorganella morganiiK. oxytoca
Agent(n=49)(n=54)(n=38)(n=17)(n=6)(n=1)(n=2)(n=2)(n=2)(n=2)
Amikacin86(42)41(22)16(6)35(6)33(2)0.0 (0)50(1)50(1)50(1)50(1)
Amoxicillin/clavulanate92(45)69(37)37(14)88(15)50(3)100(1)50(1)50(1)50(1)50(1)
Aztreonam96(47)87(47)68(26)65(11)83(5)100(1)50(1)50(1)100(2)100(2)
Cefepime94(46)82(44)66(25)82(14)50(3)0.0 (0)50(1)0.0 (0)50(1)0.0 (0)
Cefotaxime96(47)83(45)66(25)88(15)33(2)100(1)50(1)50(1)50(1)0.0 (0)
Ceftazidime94(46)80(43)71(27)59(10)50(3)0.0 (0)0.0 (0)50(1)50(1)0.0 (0)
Cefuroxime100(49)98(53)87(33)88(15)83(5)100(1)100(2)100(2)100(2)50(1)
Ciprofloxacin96(47)61(33)58(22)82(14)33(2)100(1)100(2)0.0 (0)50(1)100(2)
Colistin6(3)4.0(2)3.0(1)6.0(1)0.0 (0)0.0 (0)0.0 (0)0.0 (0)100(2)0.0 (0)
Foxitin92(45)46(25)18(7)59(10)50(3)100(1)0.0 (0)0.0 (0)100(2)50(1)
Gentamicin88(43)61(33)37(14)53(9)17(1)0.0 (0)50(1)50(1)100(2)0.0 (0)
Imipenem94(46)35(19)13(5)29(5)17(1)0.0 (0)50(1)50(1)100(2)0.0 (0)
Meropenem92(45)33(18)13(5)24(4)0.0 (0)0.0 (0)0.0 (0)0.0 (0)100(2)50(1)
Nitrofurantoin96(47)69(37)37(14)71(12)67(4)0.0 (0)100(2)0.0 (0)50(1)50(1)
Ofloxacin94(46)63(34)50(19)77(13)33(2)100(1)100(2)0.0 (0)50(1)100(2)
Piperacillin94(46)61(33)47(18)65(11)50(3)0.0 (0)50(1)50(1)100(2)50(1)
Piperacillin/tazobactam94(46)54(29)40(15)35(6)50(3)0.0 (0)50(1)50(1)100(2)50(1)
Tobramicin90(44)59(32)37(14)53(9)33(2)0.0 (0)50(1)50(1)50(1)50(1)
Trimethoprim/sulfamethoxazole96(47)87(47)92(35)100(17)100(6)100(1)100(2)50(1)50(1)100(2)
Distribution of ESBL genes among MDR isolates

Of the 173 MDR Enterobacteriaceae and A. baumannii isolates, 78 (45.1%) exhibited ESBL production. Of the 78 isolates, 72 (92.3%) carried ESBL genes as determined using multiplex-PCR. Fig. 2 presents an example of multiplex-PCR results revealed during the present study. Of the 72 isolates, 53 were Enterobacteriaceae (K. pneumoniae, 28; E. coli, 18; P. mirabilis, 5 and Enterobacter cloacae, 2) and 19 were A. baumannii (Fig. 3). Collectively, the most prevalent ESBL resistance genes in the isolates were blaTEM (84.7%) followed by blaCTX-M (33.3%), blaSHV (2.7%) and blaOXA-1 (1.4%). The most frequent blaCTX-M group was the blaCTX-M-group 1 (27.2%), followed by the blaCTX-M-group 2 and 9 (4.2%), whereas none of the isolates carried the blaCTX-M-group 8/25 (Table I).

Frequency of ESBL genes in Enterobacteriaceae and A. baumannii

Fig. 3 illustrates the distribution of ESBL genes among Gram-negative bacterial isolates. A single blaTEM gene was predominantly produced by K. pneumoniae (60.7%), A. baumannii (78.9%) and P. mirabilis (80%), while blaCTX-M was commonly produced by E. coli (33.3%).

Out of the total PCR-positive isolates (n=72), the co-existence of two different genes in a single isolate was revealed in 16 (22.2%) strains. This combination was mainly observed between blaTEM and blaCTX-M (19.4%; 14/72) and between blaTEM and blaSHV (2.8%, 2/72) genes. Among the isolates carrying a combination of blaTEM and blaCTX-M genes (n=14), the majority were K. pneumoniae (50%, n=7) and E. coli (28.6%, n=4; Fig. 3).

Distribution of ESBL genes according to isolate sources

The distribution of various ESBL resistance genes among the clinical samples of patients is revealed in Table III. Bacterial isolates encoding various ESBL resistance genes were commonly recovered from sputum (n=30), followed by urine (n=18), wound (n=13) and blood (n=8) specimens. A single blaTEM gene was frequently detected among isolates from sputum (73.3%; 22/30), urine (61.1%; 11/18) and wound (53.8%; 7/13) specimens. The highest frequency of a single blaCTX-M gene was detected among wound isolates (23.1%; 3/13) compared with sputum (10%), blood (12.5%; 1/8) and urine (11.1%; 2/18) isolates. The co-existence of blaTEM and blaCTX-M genes was observed in 37.5% (3/8) of blood isolates, 23.1% (3/13) of wound isolates and 22.2% (4/18) of urine isolates.

Table III

Distribution of extended-spectrum β-lactamase resistance genes in Gram-negative isolates recovered from clinical samples of patients.

Table III

Distribution of extended-spectrum β-lactamase resistance genes in Gram-negative isolates recovered from clinical samples of patients.

 Single geneCombined genes 
Source of Gram-negative bacteria blaTEM (n=45) blaCTX-M (n=10) blaOXA-1 (n=1) blaTEM and blaCTX-M (n=14) blaTEM and blaSHV (n=2)Total
Sputum (n=30)22313130
Urine (n=18)11204018
Wound (n=13)7303013
Blood (n=8)410308
Tracheal aspirate (n=2)010102
Eye swab (n=1)100001
Sequencing analysis of resistance genes encoding ESBL producers

The sequencing analysis of the blaCTX-M, blaTEM and blaSHV types is revealed in Table IV. Out of the 20 blaCTX-M family members, the majority (75%; n=15) carried the blaCTX-M-15 subtype. blaCTX-M-15 was identified among K. pneumoniae (n=7) and E. coli (n=5) isolates. Out of the 18 blaTEM family members, TEM-1 was the most prevalent variant (83.3%, n=15). This subtype was common among A. baumannii (n=7) and K. pneumoniae (n=5) isolates.

Table IV

Sequencing analysis results of blaCTX-M, blaTEM and blaSHV genes produced by Enterobacteriaceae members and Acinetobacter baumannii.

Table IV

Sequencing analysis results of blaCTX-M, blaTEM and blaSHV genes produced by Enterobacteriaceae members and Acinetobacter baumannii.

ESBL geneTotal (n=40)K. pneumoniae (n=13)E. coli (n=12)P. mirabilis (n=2)E. cloacae (n=3)A. baumannii (n=10)
blaCTX-M subtype (n=20)      
     CTX-M-151575111
     CTX-M-71101000
     CTX-M-101100001
     CTX-M-127101000
     CTX-M-181100010
     CTX-M-182101000
blaTEM subtype (n=18)      
     TEM-11552017
     TEM-115101000
     TEM-159100100
     TEM-169101000
blaSHV subtype (n=2)      
     SHV-28100001
     SHV-226110000

Discussion

The emergence of MDR patterns due to ESBL-producing Enterobacteriaceae and A. baumannii is becoming a global concern (13,31). The present study determined antibiotic susceptibility patterns and characterized ESBL genes among clinical isolates of Enterobacteriaceae and A. baumannii. Collectively, 63.1% of isolates exhibited MDR to different antibiotics. In addition, MDR patterns were identified in 63.5% of K. pneumoniae and 51.8% of E. coli isolates. In Riyadh, the capital of Saudi Arabia, MDR patterns were identified in 67% of uropathogenic E. coli isolates at a tertiary healthcare center (19). These values were higher than those reported in Libya, where the MDR phenotype was detected in 33.2% of E. coli and 42% of K. pneumoniae isolates from patients with urinary tract infections (32). The results were also consistent with the observed high prevalence of MDR patterns (100%)among clinical isolates of Enterobacteriaceae carrying ESBL resistance genes collected in Ethiopia (33).

In the present study, the overall resistance rates of MDR Enterobacteriaceae and A. baumannii were very high for most examined antibiotics, except for colistin. Previous studies have reported that co-resistance to several antibiotic classes of penicillins, cephalosporins, aminoglycosides, fluoroquinolones, trimethoprim/sulfamethoxazole and carbapenems was common among ESBL-producing Gram-negative bacteria (7,19,33,34). These findings indicated that the emergence of ESBL-producing microorganisms could cause susceptibility to various antibiotics.

A multiplex-PCR assay has been proposed to rapidly detect several resistance genes encoding ESBL-producing Gram-negative bacteria (28,35). However, complete gene sequencing for the blaTEM, blaSHV, blaCTX-M and blaOXA-1 types is essential to differentiate narrow-spectrum β-lactamases from ESBL (35). In the present study, among 81 phenotypically identified ESBL isolates, 88.9% carried one or more of the following resistant genes: blaTEM, blaCTX-M, blaSHV and blaOXA. Previous studies have reported that bacteria carrying ESBL genes confer resistance to extended-spectrum cephalosporins, β-lactam agents and other antibiotic classes (7,19,20). This phenomenon may pose serious public health risks, as it would result in substantial limitations in therapeutic options. Thus, appropriate control measures, including establishing screening strategies for identifying ESBL-producing bacteria, are required to prevent such strains.

blaTEM was the most prevalent gene detected in ESBL-producing Gram-negative bacteria in the present study. This was inconsistent with a study from the Eastern region of Saudi Arabia, where blaCTX-M (97.4%) was more frequent than blaSHV (23.1%) and blaTEM (0.0%) in Enterobacteriaceae (16). Similarly, the predominance of the blaCTX-M type in ESBL-producing Gram-negative bacteria in the Eastern region have been documented by other studies (4,36). Worldwide studies have reported different ESBL resistance genes produced by Gram-negative bacteria. For instance, blaCTX-M was the most prevalent type in the Asian Pacific region, followed by blaSHV and blaTEM (1). In Nigeria, the most frequent gene types among isolates from patients with surgical site infections were blaSHV, blaCTX-M and blaOXA (37). In Burkina Faso, the most prevalent ESBL resistance genes were blaCTX-M (40.1%), blaTEM (26.2%) and blaSHV (5.9%) in Enterobacteriaceae (38). These results, coupled with the present findings, revealed that the prevalence of ESBL gene types can vary between locations and geographical regions.

MDR ESBL-producing K. pneumoniae and A. baumannii have become common causes of healthcare-related infections (11,31). In the present study, the prevalence of blaTEM in K. pneumoniae was revealed to be 60.7%. Increasing rates of the blaTEM gene have been reported among clinical isolates of K. pneumoniae in Al-Qassim (70.9%) (8) and Riyadh (54.05%), in the Central region of Saudi Arabia (17). On the other hand, the frequency of blaTEM was high among A. baumannii isolates, which was consistent with a previous study from the Makkah city in the western region of the country (31). These high rates, which indicated the dissemination of such ESBL-producing isolates, is alarming for multiple hospitals. The high prevalence of the blaTEM gene detected in K. pneumoniae and A. baumannii isolates may increase the incidence rate of infection caused by these ESBL producers across different regions. This renders extensive surveillance studies in local and national hospitals in Saudi Arabia necessary to understand the transmission and epidemiology of resistance genes encoding ESBL-producing bacteria. However, using molecular methods in local hospitals to detect resistance genes may help develop effective new antimicrobial treatments against ESBL producers and improve the infection control system. In the present study, E. coli commonly produced the blaCTX-M gene (33.3%). Similarly, the predominance of E. coli carrying blaCTX-M genes has been reported in the western region of Saudi Arabia (39). Previous studies revealed that blaCTX-M is the most prevalent gene among uropathogenic E. coli isolates from patients with hospital and community-acquired infections (19,29). Furthermore, ESBL-producing E. coli collected from fecal colonization was revealed to produce the blaCTX-M gene as it has been reported in a previous study (40). Several factors and mechanisms contribute to the spread of bacterial clones carrying the blaCTX-M gene in Saudi Arabia, including plasmid dissemination and the clonal spread of bacterial strains, the frequent use of cephalosporins and the large population of migrant workers (13). According to Yasir et al (39), the high diversity in the E. coli clones may have arisen due to the fact that ~50% of the population of Saudi Arabia are expatriates from developing countries, including Pakistan, India, Bangladesh, the Philippines and African countries where self-medication in patients is evident.

The present study revealed that blaCTX-M-15 was the most frequent subtype of the blaCTX-M type. This was consistent with data from Saudi Arabia (6,16,17) and several other parts of the world (1,2). These findings indicated that blaCTX-M-15 is a public health concern, since it is the most widespread gene worldwide. The emergence of the blaCTX-M-15 variant has been revealed to be attributed to the horizontal gene transfer of genetic elements and the clonal expansion of microorganisms (19,41). Furthermore, the widespread and unnecessary use of ceftriaxone and cefotaxime have contributed to the emergence and spread of blaCTX-M resistance genes (2).

Multiple ESBL resistance genes in a single bacterium render that strain more difficult to treat with several antibiotic drugs (16). In the present study, the co-existence of two different ESBL genes in the same strain was detected in 22.2% of isolates. However, the most common combination of ESBL resistance genes was between blaTEM and blaCTX-M, which was consistent with studies from Pakistan (42) and Algeria (12). However, the combined production of blaTEM and blaCTX-M genes was more frequently detected in K. pneumoniae (50%) and E. coli (28.6%) isolates. These figures were lower than those reported in Nepal, where two or more ESBL genes were present in 100% of Klebsiella spp. and 56.2% of E. coli clinical isolates from a teaching hospital (7). The value reported in the present study was considerably higher than the 3.4% reported in uropathogenic E. coli from the Eastern region of Saudi Arabia (29).

The present findings revealed that sputum was the most frequent source of various ESBL resistance genes in Gram-negative bacteria. This may be due to the several sputum samples collected from patients at intensive care unit (ICU) wards. A previous study indicated that the characterization of antibiotic susceptibility of bacterial pathogens from the sputum of patients in the ICU with ventilator-associated pneumonia can help control this type of infection (43). In addition, it is known that most patients admitted to the ICU are immunocompromised and/or undergoing invasive procedures, which would lead to prolonged antibiotic therapy (25). The extended stay, selective pressure and frequent use of antibiotic treatment of patients in the ICU contribute to the increase in ESBL producers (43).

The present study has several limitations that need to be addressed in future studies. Firstly, the study was laboratory-based; therefore, clinical data of the patients were not obtained to analyze the risk factors for ESBL infection and understand the epidemiological spread of ESBL genes. Secondly, the study was conducted in a single center in southern Saudi Arabia. The results can therefore not be representative of all parts of the southern region. Multicenter studies are required to confirm these findings. Thirdly, the AmpC β-lactamase class and other types of ESBL enzymes, (such as blaVEB, blaPER, blaGES and blaBEL) which confer significant antibiotic resistance among Gram-negative bacteria, were not examined.

In conclusion, the ESBL resistance genes were a significant cause of MDR patterns and conferred susceptibility to various antibiotic agents in Enterobacteriaceae and A. baumannii. The present study reported high levels of various resistance genes in ESBL-producing isolates, with blaTEM being the most prevalent type. In addition, the co-existence of two different ESBL genes has been frequently detected in a single bacterial pathogen (12,42). The blaCTX-M-15 gene is the predominant variant among isolates carrying the blaCTX-M type. The emergence of various ESBL-resistant and coexisting genes in Enterobacteriaceae and A. baumannii is alarming and may significantly limit the efficacy of therapeutic options in hospital settings. However, extensive surveillance studies at both the local and national levels are urgently required to obtain an understanding of the transmission and epidemiology of resistance genes in ESBL-producing bacteria. Using molecular methods at local hospitals to detect resistance genes in ESBL-producing bacteria is recommended to improve the infection control system and help set effective antibiotic therapy plans.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Deanship of Scientific Research at University of Bisha (Bisha, Saudi Arabia), as a part of project number UB-12-1438.

Availability of data and materials

All data generated or analyzed during the study are included in this published article. The datasets generated during the present study are available in the Genbank repository, (http://getentry.ddbj.nig.ac.jp/; accession numbers LC636038- LC636063).

Authors' contributions

MEI, TBA, MA and BKE conceived the idea of the study and developed the protocol. MEI and MA designed and conducted the study. MEI and TBA analyzed and interpreted the data and wrote the initial draft. MEI, TBA, MA, BKE reviewed the literature. BKE revised the study for important intellectual contents. MEI and BKE confirm the authenticity of all the raw data. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

The Research and Ethics Committee at the College of Medicine, University of Bisha (Bisha, Saudi Arabia) reviewed and approved the present study protocol.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Sheng WH, Badal RE and Hsueh PR: SMART Program. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: Results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 57:2981–2988. 2013.PubMed/NCBI View Article : Google Scholar

2 

Manyahi J, Moyo SJ, Tellevik MG, Ndugulile F, Urassa W, Blomberg B and Langeland N: Detection of CTX-M-15 beta-lactamases in Enterobacteriaceae causing hospital- and community-acquired urinary tract infections as early as. 2004, in Dar es Salaam, Tanzania. BMC Infect Dis. 17(282)2017.PubMed/NCBI View Article : Google Scholar

3 

Jiang W, Yang W, Zhao X, Wang N and Ren H: Klebsiella pneumoniae presents antimicrobial drug resistance for β-lactam through the ESBL/PBP signaling pathway. Exp Ther Med. 19:2449–2456. 2020.PubMed/NCBI View Article : Google Scholar

4 

Hassan MI, Alkharsah KR, Alzahrani AJ, Obeid OE, Khamis AH and Diab A: Detection of extended spectrum beta-lactamases-producing isolates and effect of AmpC overlapping. J Infect Dev Ctries. 7:618–629. 2013.PubMed/NCBI View Article : Google Scholar

5 

Marie MA, John J, Krishnappa LG and Gopalkrishnan S: Molecular characterization of the β-lactamases in Escherichia coli and Klebsiella pneumoniae from a tertiary care hospital in Riyadh, Saudi Arabia. Microbiol Immunol. 57:805–810. 2013.PubMed/NCBI View Article : Google Scholar

6 

Yezli S, Shibl AM and Memish ZA: The molecular basis of β-lactamase production in Gram-negative bacteria from Saudi Arabia. J Med Microbiol. 64:127–136. 2015.PubMed/NCBI View Article : Google Scholar

7 

Parajuli NP, Maharjan P, Joshi G and Khanal PR: Emerging Perils of Extended Spectrum β-Lactamase Producing Enterobacteriaceae Clinical Isolates in a Teaching Hospital of Nepal. BioMed Res Int. 2016:p1–7. 2016.PubMed/NCBI View Article : Google Scholar

8 

Tawfik AF, Alswailem AM, Shibl AM and Al-Agamy MHM: Prevalence and genetic characteristics of TEM, SHV, and CTX-M in clinical Klebsiella pneumoniae isolates from Saudi Arabia. Microb Drug Resist. 17:383–388. 2011.PubMed/NCBI View Article : Google Scholar

9 

Dirar MH, Bilal NE, Ibrahim ME and Hamid ME: Prevalence of extended-spectrum β-lactamase (ESBL) and molecular detection of blaTEM, blaSHV and blaCTX-M genotypes among Enterobacteriaceae isolates from patients in Khartoum, Sudan. Pan Afr Med J. 37(213)2020.PubMed/NCBI View Article : Google Scholar

10 

Shahcheraghi F: Haleh Moezi MMF: Distribution of TEM and SHV beta-lactamase genes among Klebsiella pneumoniae strains isolated from patients in Tehran. Med Sci Monit. 13:BR247–BR251. 2007.PubMed/NCBI

11 

Somily AM, Habib HA, Absar MM, Arshad MZ, Manneh K, Al Subaie SS, Al Hedaithy MA, Sayyed SB, Shakoor Z and Murray TS: ESBL-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care hospital in Saudi Arabia. J Infect Dev Ctries. 8:1129–1136. 2014.PubMed/NCBI View Article : Google Scholar

12 

Nedjai S, Barguigua A, Djahmi N, Jamali L, Zerouali K, Dekhil M and Timinouni M: Prevalence and characterization of extended spectrum beta-lactamase-producing Enterobacter cloacae strains in Algeria. J Infect Dev Ctries. 7:804–811. 2013.PubMed/NCBI View Article : Google Scholar

13 

Zowawi HM, Balkhy HH, Walsh TR and Paterson DL: β-lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula. Clin Microbiol Rev. 26:361–380. 2013.PubMed/NCBI View Article : Google Scholar

14 

Alyamani EJ, Khiyami AM, Booq RY, Majrashi MA, Bahwerth FS and Rechkina E: The occurrence of ESBL-producing Escherichia coli carrying aminoglycoside resistance genes in urinary tract infections in Saudi Arabia. Ann Clin Microbiol Antimicrob. 16(1)2017.PubMed/NCBI View Article : Google Scholar

15 

Al-Agamy MHM, Shibl AM and Tawfik AF: Prevalence and molecular characterization of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in Riyadh, Saudi Arabia. Ann Saudi Med. 29:253–257. 2009.PubMed/NCBI View Article : Google Scholar

16 

Hassan H and Abdalhamid B: Molecular characterization of extended-spectrum beta-lactamase producing Enterobacteriaceae in a Saudi Arabian tertiary hospital. J Infect Dev Ctries. 8:282–288. 2014.PubMed/NCBI View Article : Google Scholar

17 

Al-Qahtani AA, Al-Agamy MH, Ali MS, Al-Ahdal MN, Aljohi MA and Shibl AM: Characterization of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae from Riyadh, Saudi Arabia. J Chemother. 26:139–145. 2014.PubMed/NCBI View Article : Google Scholar

18 

Al-Agamy MH, Shibl AM, Hafez MM, Al-Ahdal MN, Memish ZA and Khubnani H: Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli in Riyadh: Emergence of CTX-M-15-producing E. coli ST131. Ann Clin Microbiol Antimicrob. 13(4)2014.PubMed/NCBI View Article : Google Scholar

19 

Alqasim A, Abu Jaffal A and Alyousef AA: Prevalence of Multidrug Resistance and Extended-Spectrum β-lactamase Carriage of Clinical Uropathogenic Escherichia coli Isolates in Riyadh, Saudi Arabia. Int J Microbiol. 2018(3026851)2018.PubMed/NCBI View Article : Google Scholar

20 

Ibrahim ME, Abbas M, Al-Shahrai AM and Elamin BK: Phenotypic Characterization and Antibiotic Resistance Patterns of Extended-Spectrum β-Lactamase- and AmpC β-Lactamase-Producing Gram-Negative Bacteria in a Referral Hospital, Saudi Arabia. Can J Infect Dis Med Microbiol. 2019(6054694)2019.PubMed/NCBI View Article : Google Scholar

21 

Al-Garni SM, Ghonaim MM, Ahmed MMM, Al-Ghamdi AS and Ganai FA: Risk factors and molecular features of extended-spectrum beta-lactamase producing bacteria at southwest of Saudi Arabia. Saudi Med J. 39:1186–1194. 2018.PubMed/NCBI View Article : Google Scholar

22 

Al Bshabshe A, Joseph MRP, Al Hussein A, Haimour W and Hamid ME: Multidrug resistance Acinetobacter species at the intensive care unit, Aseer Central Hospital, Saudi Arabia: A one year analysis. Asian Pac J Trop Med. 9:903–908. 2016.PubMed/NCBI View Article : Google Scholar

23 

Elabd FM, Al-Ayed MSZ, Asaad AM, Alsareii SA, Qureshi MA and Musa HA-A: Molecular characterization of oxacillinases among carbapenem-resistant Acinetobacter baumannii nosocomial isolates in a Saudi hospital. J Infect Public Health. 8:242–247. 2015.PubMed/NCBI View Article : Google Scholar

24 

Almaghrabi MK, Joseph MRP, Assiry MM and Hamid ME: Multidrug-Resistant Acinetobacter baumannii: An Emerging Health Threat in Aseer Region, Kingdom of Saudi Arabia. Can J Infect Dis Med Microbiol. 2018(9182747)2018.PubMed/NCBI View Article : Google Scholar

25 

Ibrahim ME: High antimicrobial resistant rates among Gram-negative pathogens in intensive care units. A retrospective study at a tertiary care hospital in Southwest Saudi Arabia. Saudi Med J. 39:1035–1043. 2018.PubMed/NCBI View Article : Google Scholar

26 

Jarlier V, Nicolas MH, Fournier G and Philippon A: Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev Infect Dis. 10:867–878. 1988.PubMed/NCBI View Article : Google Scholar

27 

Clinical and Laboratory Standards Institute (CLSI): Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Seventh Informational Supplement. Document M100-S27. CLSI, Wayne, PA, 2017.

28 

Dallenne C, Da Costa A, Decré D, Favier C and Arlet G: Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 65:490–495. 2010.PubMed/NCBI View Article : Google Scholar

29 

Mashwal FA, El Safi SH, George SK, Adam AA and Jebakumar AZ: Incidence and molecular characterization of the extended spectrum beta lactamase-producing Escherichia coli isolated from urinary tract infections in Eastern Saudi Arabia. Saudi Med J. 38:811–815. 2017.PubMed/NCBI View Article : Google Scholar

30 

Gupta V, Ye G, Olesky M, Lawrence K, Murray J and Yu K: Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013-2017. BMC Infect Dis. 19(742)2019.PubMed/NCBI View Article : Google Scholar

31 

Alyamani EJ, Khiyami MA, Booq RY, Alnafjan BM, Altammami MA and Bahwerth FS: Molecular characterization of extended-spectrum beta-lactamases (ESBLs) produced by clinical isolates of Acinetobacter baumannii in Saudi Arabia. Ann Clin Microbiol Antimicrob. 14(38)2015.PubMed/NCBI View Article : Google Scholar

32 

Abujnah AA, Zorgani A, Sabri MAM, Mohammady HE, Khalek RA and Ghenghesh KS: Multidrug resistance and extended-spectrum β-lactamases genes among Escherichia coli from patients with urinary tract infections in Northwestern Libya. Libyan J Med. 10(26412)2015.PubMed/NCBI View Article : Google Scholar

33 

Zeynudin A, Pritsch M, Schubert S, Messerer M, Liegl G, Hoelscher M, Belachew T and Wieser A: Prevalence and antibiotic susceptibility pattern of CTX-M type extended-spectrum β-lactamases among clinical isolates of gram-negative bacilli in Jimma, Ethiopia. BMC Infect Dis. 18(524)2018.PubMed/NCBI View Article : Google Scholar

34 

Dirar M, Bilal N, Ibrahim ME and Hamid M: Resistance Patterns and Phenotypic Detection of β -lactamase Enzymes among Enterobacteriaceae Isolates from Referral Hospitals in Khartoum State, Sudan Bacterial isolates and antimicrobial susceptibility testing. Cureus. 12(e7260)2020.PubMed/NCBI View Article : Google Scholar

35 

Woodford N: Rapid characterization of beta-lactamases by multiplex PCR. Methods Mol Biol. 642:181–192. 2010.PubMed/NCBI View Article : Google Scholar

36 

Bindayna K, Khanfar HS, Senok AC and Botta GA: Predominance of CTX-M genotype among extended spectrum beta lactamase isolates in a tertiary hospital in Saudi Arabia. Saudi Med J. 31:859–863. 2010.PubMed/NCBI

37 

Olowo-Okere A, Ibrahim YKE and Olayinka BO: Molecular characterisation of ESBL producing Gram-negative bacterial isolates from surgical wounds of patients at a hospital in north central Nigeria. J Glob Antimicrob Resist. 14:85–89. 2018.PubMed/NCBI View Article : Google Scholar

38 

Kpoda DS, Ajayi A, Somda M, Traore O, Guessennd N, Ouattara AS, Sangare L, Traore AS and Dosso M: Distribution of resistance genes encoding ESBLs in Enterobacteriaceae isolated from biological samples in health centers in Ouagadougou, Burkina Faso. BMC Res Notes. 11(471)2018.PubMed/NCBI View Article : Google Scholar

39 

Yasir M, Ajlan AM, Shakil S, Jiman-Fatani AA, Almasaudi SB, Farman M, Baazeem ZM, Baabdullah R, Alawi M, Al-Abdullah N, et al: Molecular characterization, antimicrobial resistance and clinico-bioinformatics approaches to address the problem of extended-spectrum β-lactamase-producing Escherichia coli in western Saudi Arabia. Sci Rep. 8(14847)2018.PubMed/NCBI View Article : Google Scholar

40 

Al-Agamy MH, El Mahdy TS and Shibl AM: Fecal Colonization with Extended-Spectrum Beta-Lactamase and AmpC-Producing Escherichia coli. BioMed Res Int. 2016(3704150)2016.PubMed/NCBI View Article : Google Scholar

41 

Barguigua A, El Otmani F, Talmi M, Bourjilat F, Haouzane F, Zerouali K and Timinouni M: Characterization of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from the community in Morocco. J Med Microbiol. 60:1344–1352. 2011.PubMed/NCBI View Article : Google Scholar

42 

Habeeb MA, Sarwar Y, Ali A, Salman M and Haque A: Rapid emergence of ESBL producers in E. coli causing urinary and wound infections in Pakistan. Pak J Med Sci. 29:540–544. 2013.PubMed/NCBI View Article : Google Scholar

43 

Ning BT, Zhang CM, Liu T, Ye S, Yang ZH and Chen ZJ: Pathogenic analysis of sputum from ventilator-associated pneumonia in a pediatric intensive care unit. Exp Ther Med. 5:367–371. 2013.PubMed/NCBI View Article : Google Scholar

Related Articles

Journal Cover

December-2021
Volume 22 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ibrahim ME, Algak TB, Abbas M and Elamin BK: Emergence of <em>bla</em><sub>TEM</sub>, <em>bla</em><sub>CTX‑M</sub>, <em>bla</em><sub>SHV</sub> and <em>bla</em><sub>OXA</sub> genes in multidrug‑resistant <em>Enterobacteriaceae</em> and <em>Acinetobacter baumannii</em> in Saudi Arabia. Exp Ther Med 22: 1450, 2021.
APA
Ibrahim, M.E., Algak, T.B., Abbas, M., & Elamin, B.K. (2021). Emergence of <em>bla</em><sub>TEM</sub>, <em>bla</em><sub>CTX‑M</sub>, <em>bla</em><sub>SHV</sub> and <em>bla</em><sub>OXA</sub> genes in multidrug‑resistant <em>Enterobacteriaceae</em> and <em>Acinetobacter baumannii</em> in Saudi Arabia. Experimental and Therapeutic Medicine, 22, 1450. https://doi.org/10.3892/etm.2021.10885
MLA
Ibrahim, M. E., Algak, T. B., Abbas, M., Elamin, B. K."Emergence of <em>bla</em><sub>TEM</sub>, <em>bla</em><sub>CTX‑M</sub>, <em>bla</em><sub>SHV</sub> and <em>bla</em><sub>OXA</sub> genes in multidrug‑resistant <em>Enterobacteriaceae</em> and <em>Acinetobacter baumannii</em> in Saudi Arabia". Experimental and Therapeutic Medicine 22.6 (2021): 1450.
Chicago
Ibrahim, M. E., Algak, T. B., Abbas, M., Elamin, B. K."Emergence of <em>bla</em><sub>TEM</sub>, <em>bla</em><sub>CTX‑M</sub>, <em>bla</em><sub>SHV</sub> and <em>bla</em><sub>OXA</sub> genes in multidrug‑resistant <em>Enterobacteriaceae</em> and <em>Acinetobacter baumannii</em> in Saudi Arabia". Experimental and Therapeutic Medicine 22, no. 6 (2021): 1450. https://doi.org/10.3892/etm.2021.10885